Article Versions Notes

Donà C, Koschutnik M, Nitsche C, Winter M-P, Seidl V, Siller-Matula J, Mach M, Andreas M, Bartko P, Kammerlander AA, et al. Cerebral Protection in TAVR—Can We Do Without? A Real-World All-Comer Intention-to-Treat Study—Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality. Journal of Personalized Medicine. 2022; 12(2):320. https://doi.org/10.3390/jpm12020320

Donà, Carolina, Matthias Koschutnik, Christian Nitsche, Max-Paul Winter, Veronika Seidl, Jolanta Siller-Matula, Markus Mach, Martin Andreas, Philipp Bartko, Andreas Anselm Kammerlander, and et al. 2022. "Cerebral Protection in TAVR—Can We Do Without? A Real-World All-Comer Intention-to-Treat Study—Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality" Journal of Personalized Medicine 12, no. 2: 320. https://doi.org/10.3390/jpm12020320

Donà, C., Koschutnik, M., Nitsche, C., Winter, M. -P., Seidl, V., Siller-Matula, J., Mach, M., Andreas, M., Bartko, P., Kammerlander, A. A., Goliasch, G., Lang, I., Hengstenberg, C., & Mascherbauer, J. (2022). Cerebral Protection in TAVR—Can We Do Without? A Real-World All-Comer Intention-to-Treat Study—Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality. Journal of Personalized Medicine, 12(2), 320. https://doi.org/10.3390/jpm12020320